Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Xigris er større end risiciene for patienter med svær sepsis og svigt af flere organer.
The Committee for Medicinal Products for Human Use (CHMP) decided that Xigris’ s benefits are greater than its risks for patients with severe sepsis and multiple organ failure.